Focus: Ark Biosciences is a Shanghai-based biotechnology company founded in 2021, focused on developing therapeutics for respiratory virus infections. The company operates as a pre-revenue stage biotech with early-stage clinical programs.
Profile data last refreshed 4h ago · AI intelligence enriched 3w ago
Stable — net +4 jobs in 30d
6 added, 2 removed. Backfill posture.
Ark Biosciences is a high-risk, high-reward early-stage biotech bet suitable only for founders-minded scientists willing to accept uncertainty for equity upside in respiratory therapeutics.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Ark Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ark Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo